Skip to content

Ayurveda Rasayan therapy for reducing risk of COVID infection in high risk individuals with comorbidities

Reducing the risk of developing symptomatic Corona virus disease and reducing requirement of hospitalization by administering Ayurveda Rasayana therapy as a prophylactic therapy to individuals residing Coronavirus Hotspots and having comorbidities which increases the risk of developing severe stage Coronavirus disease or ARDS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026568
Enrollment
60
Registered
2020-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Pragmatic clinical study which studies the whole system personalised approch of meedcine practice.: The investigator can prescribe the medcine which are based on his clinical logical .T

Sponsors

Ayurved Rasayani
Lead Sponsor
Ayurved Rasayani
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 Individuals residing in Corona virus Hotspots as declared by Authorities 2 Individuals having any of the following comorbidities 3 Chronic Diabetic with more than 5 yearsof knownon set Chronic hypertensive with more than 5years of knownon set Patients with active malignancies or taking or taken anticancer therapy within last 6months Patients with chronic lowerrespiratory disease Patients with chronic liver or renalfailure Patients having immunosuppressivetherapies Or elderly person above 65 years of age with or without any comorbidities

Exclusion criteria

Exclusion criteria: Pregnant women or women who are breast feeding Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive study treatment

Design outcomes

Primary

MeasureTime frame
Incidence of individual becoming positive as determined by PCR or any other approved commercial or public health assays Timepoint: Time Frame on day 30 or development of symptoms of corona virus disease Severe stage

Secondary

MeasureTime frame
Secondary outcomes Disease severity on an ordinal scale assessed on at weekly intervals telephonically. Duration of stay in ICU Percent mortality Adverse events CBC LFT RFT At baseline and day 30 Timepoint: Day 1 Day 30 and Day 60

Countries

India

Contacts

Public ContactDr Ketaki Jagtap

Rasayu Ayurved Clinic

physician1@rasayuayurvedclinic.com9766897894

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026